http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105753863-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105753863-B |
| titleOfInvention | Oxo-dihydro Imidazopyridine compound and its application |
| abstract | The present invention provides 2 oxos 1 indicated by leading to formula (I), 3 glyoxalidine and pyridine compounds and their and its application in the drug for preparing the various diseases that treatment bruton's tyrosine kinase (Bruton ' s tyrosine kinase, BTK) is participated in.Research has shown that compound disclosed by the invention can effectively inhibit the activity of BTK, and then by inhibiting BTK to prevent existence, proliferation and the diffusion of Hematological malignancies cell.In addition, by inhibiting BTK can be to anti-inflammatory and autoimmune disease.Therefore, the compound of the present invention can be used in the various diseases that treatment BTK is participated in has larger application value especially suitable for the treatment of hematologic malignancies and inflammation and autoimmune disease. |
| priorityDate | 2015-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 365.